Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Gilead Sciences Inc (GILD) reports robust financial performance with significant sales growth in key therapeutic areas and ...

On Tuesday, Gilead Sciences, Inc. (GILD) stock saw a modest uptick, ending the day at $85.21 which represents a slight increase of $0.78 or 0.92% from the prior close of $84.43. The stock opened at ...

Future Financial Wealth Managment LLC acquired a new stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) in ...

In the latest market close, Gilead Sciences (GILD) reached $85.21, with a +0.92% movement compared to the previous day. The stock's performance was behind the S&P 500's daily gain of 0.97%. Meanwhile, ...

Despite major advances in scientific innovation, access to care and growth of health systems, there are still millions of people around the world living with HIV.

Gilead Merger AstraZeneca, the UK’s largest drugmaker valued at $140bn, has reportedly contacted Gilead Sciences, an American ...

The stock's fall snapped a five-day winning streak.

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Accolade (ACCD – Research Report) and Gilead ...

Analyst Michael Yee from Jefferies maintained a Buy rating on Gilead Sciences (GILD – Research Report) and keeping the price target at ...

Gilead Sciences said on Thursday it would donate about 5,000 vials of its antiviral drug remdesivir to the Rwanda Medical ...

Fintel reports that on October 7, 2024, Wells Fargo upgraded their outlook for Gilead Sciences (NasdaqGS:GILD) from ...